Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Benjamin I. Rubin is active.

Publication


Featured researches published by Benjamin I. Rubin.


Annals of Internal Medicine | 1991

A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS

Alan G. Palestine; Michael A. Polis; Marc D. de Smet; Barbara Baird; Judith Falloon; Joseph A. Kovacs; Richard T. Davey; John Zurlo; Kathryn M. Zunich; Matthew D. Davis; Larry D. Hubbard; Frederick L. Ferris; Emily Y. Chew; Janet L. Davis; Benjamin I. Rubin; Susan D. Mellow; Julia A. Metcalf; Jody Manischewitz; James R. Minor; Robert B. Nussenblatt; Henry Masur; H. Clifford Lane

OBJECTIVE To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS. PATIENTS Twenty-four previously untreated persons with AIDS and cytomegalovirus retinitis who were at low risk for loss of their visual acuity. INTERVENTION PATIENTS were randomly assigned to receive either no therapy (delayed treatment, control group) or immediate treatment with intravenous foscarnet at a dose of 60 mg/kg body weight three times a day for 3 weeks (induction regimen) followed by a maintenance regimen of 90 mg/kg once a day. MEASUREMENTS PATIENTS were examined weekly until they reached the primary clinical end point, defined as progression of their retinitis border by 750 microns or the development of a new retinal lesion due to cytomegalovirus. Progression was evaluated using retinal photographs by masked readers. Secondary evaluations included changes in visual acuity, cytomegalovirus shedding in the blood and urine, serum levels of human immunodeficiency virus type 1 (HIV-1) p24 antigen, and total CD4 T lymphocyte counts. RESULTS The mean time to progression of retinitis was 3.2 weeks in the control group (n = 11) compared with 13.3 weeks in the treatment group (n = 13) (P less than 0.001). Nine of 13 patients in the treatment group had positive blood cultures for cytomegalovirus at entry and all nine cleared their blood of cytomegalovirus by the end of the induction period (P = 0.004) compared with one of six patients in the control group. No reductions in p24 levels were seen in the control patients compared with a reduction of more than 50% in p24 levels for all four patients on treatment for whom follow-up levels were available. The main adverse effects of foscarnet treatment were seizures (2 of 13 patients), hypomagnesemia (9 of 13), hypocalcemia (11 of 13), and elevations in serum creatinine above 176.8 mumol/L (2.0 mg/dL) (3 of 13). The control patients received an average of 0.2 units of blood per week compared with an average of 0.6 units of blood per week for the patients on treatment. CONCLUSIONS The administration of foscarnet decreases the rate of progression of cytomegalovirus retinitis in persons with AIDS. Its judicious use is likely to prevent loss of vision in these patients. In this study, however, there was little change in visual acuity in patients in either the immediate or delayed treatment group because only patients with non-sight-threatening disease were selected.


Ophthalmology | 1993

Intraocular lymphoma : clinical and histopathologic diagnosis

Scott M. Whitcup; M. D. De Smet; Benjamin I. Rubin; Alan G. Palestine; Daniel F. Martin; Miguel Burnier; Chi-Chao Chan; Robert B. Nussenblatt

BACKGROUND Intraocular lymphoma is associated with significant morbidity and mortality, but early diagnosis and treatment may improve prognosis. METHODS The diagnostic features of 12 cases of intraocular lymphoma diagnosed at the National Eye Institute between 1984 and 1992 were retrospectively reviewed. RESULTS A pathologic diagnosis of large B-cell lymphoma was made on vitrectomy specimens in ten patients, cerebral spinal fluid in one, and on an enucleation specimen in one. The mean time from onset of symptoms to diagnosis was 21.4 months (range, 1-66 months). All 12 patients were given a final diagnosis of non-Hodgkins lymphoma of the central nervous system (NHL-CNS), based on the epidemiology, pathology, and clinical course of their tumors. Although an initial vitrectomy was negative for malignant cells in three of ten patients, a repeat vitrectomy specimen subsequently showed intraocular lymphoma. Results of examination of the cerebrospinal fluid (CSF) showed malignant cells in 5 of 11 patients, although malignant cells were only identified after repeat examination of additional samples of CSF in three of these patients. Malignant cells often are difficult to identify, and an experienced cytopathologist was critical in making the correct diagnosis. In addition, corticosteroids are lympholytic to the lymphoma cells, and they appeared to decrease the viability of tumor cells obtained in samples of vitreous and CSF. CONCLUSION The prompt, appropriate handling of specimens and review by an experienced cytopathologist are critical to the diagnosis of intraocular lymphoma. Malignant cells often are present in the cerebral spinal fluid at the time that ocular lymphoma is diagnosed. Nevertheless, multiple vitrectomies and lumbar punctures may be necessary before the correct diagnosis is made.


Journal of Immunotherapy | 2004

Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma A New Cause of Uveitis

Michael R. Robinson; Chi-Chao Chan; James Chih-Hsin Yang; Benjamin I. Rubin; Gerald J. Gracia; H. Nida Sen; Karl G. Csaky; Steven A. Rosenberg

Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.


American Journal of Human Genetics | 2005

Mutations in PIP5K3 Are Associated with François-Neetens Mouchetée Fleck Corneal Dystrophy

Shouling Li; Leila Tiab; Xiaodong Jiao; Francis L. Munier; Leonidas Zografos; Beatrice E. Frueh; Yuri V. Sergeev; Janine A. Smith; Benjamin I. Rubin; Mario A. Meallet; Richard K. Forster; J. Fielding Hejtmancik; Daniel F. Schorderet

François-Neetens fleck corneal dystrophy (CFD) is a rare, autosomal dominant corneal dystrophy characterized by numerous small white flecks scattered in all layers of the stroma. Linkage analysis localized CFD to a 24-cM (18-Mb) interval of chromosome 2q35 flanked by D2S2289 and D2S126 and containing PIP5K3. PIP5K3 is a member of the phosphoinositide 3-kinase family and regulates the sorting and traffic of peripheral endosomes that contain lysosomally directed fluid phase cargo, by controlling the morphogenesis and function of multivesicular bodies. Sequencing analysis disclosed missense, frameshift, and/or protein-truncating mutations in 8 of 10 families with CFD that were studied, including 2256delA, 2274delCT, 2709C-->T (R851X), 3120C-->T (Q988X), IVS19-1G-->C, 3246G-->T (E1030X), 3270C-->T (R1038X), and 3466A-->G (K1103R). The histological and clinical characteristics of patients with CFD are consistent with biochemical studies of PIP5K3 that indicate a role in endosomal sorting.


American Journal of Medical Genetics Part A | 2005

Stickler Syndrome: Clinical Characteristics and Diagnostic Criteria

Peter S. Rose; Howard P. Levy; Ruth M. Liberfarb; Joie Davis; Yvonne M. Szymko-Bennett; Benjamin I. Rubin; Ekaterini Tsilou; Andrew J. Griffith; Clair A. Francomano

The purpose of this study was to establish diagnostic criteria for Stickler syndrome. Ninety patients from 38 families had complete evaluations for possible Stickler syndrome. Molecular confirmation of COL2A1 mutation status (type I Stickler syndrome) was available on 25 patients from six families. In the remaining 65 patients, 47 from 25 families were affected with Stickler syndrome and 18 from seven families were unaffected with Stickler syndrome. A diagnostic nosology based on type I Stickler patients with known COL2A1 mutations was applied to clinically affected and unaffected patients. A diagnostic scale of 9 points evaluated molecular data or family history data and characteristic ocular, orofacial, auditory, and musculoskeletal findings. A score of ≥5 was diagnostic of Stickler syndrome. These criteria demonstrate 100% sensitivity when applied to type I Stickler syndrome patients with known COL2A1 mutations, 98% sensitivity when applied to clinically affected Stickler patients, and 86% specificity when applied to patients unaffected based on clinical and/or molecular analysis. We conclude that diagnostic criteria based on type I Stickler patients with molecularly confirmed COL2A1 mutations appear to be sensitive and specific for the diagnosis of this syndrome and should be helpful to clinicians when making the diagnosis.


Cornea | 2002

Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis.

Ekaterini Tsilou; Benjamin I. Rubin; George F. Reed; Fumino Iwata; William A. Gahl; Muriel I. Kaiser-Kupfer

Purpose. As a result of successful renal transplantation, patients with nephropathic cystinosis are now living into adulthood. As these patients age, anterior segment ocular complications, other than deposition of corneal crystals, become more evident. With our experience with 172 patients followed up at the National Institutes of Health between 1976 and 2000, the prevalence of anterior segment complications in nephropathic cystinosis was determined. Methods. A cross-sectional examination of age-specific prevalence was performed with logistic regression analysis of prevalence change with age. Results. Besides the corneal crystals apparent in all age groups, superficial punctate keratopathy, filamentary keratopathy, severe peripheral corneal neovascularization, band keratopathy, and posterior synechiae with iris thickening and transillumination were noted in the older age groups. The prevalence increased with age for each complication. Conclusions. As patients with cystinosis grow older, more severe ophthalmic manifestations become evident. It remains to be seen how the prevalence of these complications will be altered by early initiation of oral and topical cysteamine therapy.


American Journal of Ophthalmology | 1993

A Masked, Randomized, Dose-response Study Between Cyclosporine A and G in the Treatment of Sight-threatening Uveitis of Noninfectious Origin

Robert B. Nussenblatt; Marc D. de Smet; Benjamin I. Rubin; Valeria Freidlin; Scott M. Whitcup; Janet L. Davis; David C. Herman; Jeffrey N. Bloom; Pushpa Sran; Susan Whitcher; Alan G. Palestine; Howard A. Austin

Thirty-two patients with sight-threatening uveitis and a decrease in visual acuity requiring systemic therapy were randomly assigned to either cyclosporine A or G in a dose-escalation study. Groups received from 2.5 mg/kg of body weight/day to 10 mg/kg of body weight/day of either drug along with low-dose prednisone. More patients taking cyclosporine G had improved visual acuity and a decrease in macular edema, which occurred more rapidly than in the other group, even at the lower doses tested. No difference in renal function was noted between groups at any doses tested. Four patients receiving cyclosporine G had hepatic alterations, but only one required cessation of the drug. The study indicates the potential usefulness of cyclosporine G, particularly at lower doses (4 mg/kg of body weight/day), which could lower the potential for serious renal complications.


Cornea | 1991

Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with AIDS.

Rubens Belfort; de Smet M; Scott M. Whitcup; Carlos Pavesio; Lottenberg C; Benjamin I. Rubin; Juan S. Lopez; Robert B. Nussenblatt

Recent reports suggest that acquired immunodeficiency syndrome (AIDS) patients are at higher risk of developing mucocutaneous reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome (SJS). Resultant dry eye may be further exacerbated by human immunodeficiency virus (HIV) related lacrimal gland dysfunction and lead to a chronic keratoconjunctivitis. We report one patient with AIDS and toxic epidermal necrolysis and two patients with AIDS and SJS who developed severe dry eye misdiagnosed as infectious keratoconjunctivitis. Cicatrizing mucocutaneous reactions should be suspected in AIDS patients and the dry eye treated to control symptoms and prevent complications.


American Journal of Ophthalmology | 1990

Histopathologic study of the molteno glaucoma implant in three patients

Benjamin I. Rubin; Chi-Chao Chan; M N Burnier; Lucille Munion; Jeffrey Freedman

Three eyes with the Molteno glaucoma implant (one eye with epithelial downgrowth, one eye with iridocorneal endothelial syndrome, and one eye with aphakia and glaucoma) were enucleated two to six years after implantation. Histopathologic examinations disclosed no evidence of erosion of sclera or conjunctiva of the eye by the glaucoma implant device. In the outer layers of the bleb wall, few and mostly degenerated inflammatory cells were present, which represented a minimal inflammatory reaction. Scanning electron microscopy of the tubes in these three patients showed that the tube was intact, patent, and without signs of degradation. The tube entering into the anterior chamber caused no appreciable inflammation and maintained its patency even when downgrowth epithelial cells lined the anterior chamber. The Molteno plate induced little or no inflammatory reaction. Therefore, the Molteno glaucoma implant is a useful device for patients with high risk for failure after surgery for glaucoma.


American Journal of Medical Genetics Part A | 2004

Eyelid myxoma in Carney complex without PRKAR1A allelic loss.

Ekaterini Tsilou; Chi-Chao Chan; Fabiano Sandrini; Benjamin I. Rubin; De Fen Shen; J. Aidan Carney; Muriel I. Kaiser-Kupfer; Constantine A. Stratakis

Eyelid nodules were investigated in a patient with Carney complex who was heterozygous for the most commonly known PRKAR1A‐inactivating mutation, c.578delTG. Immunohistochemical studies confirmed the diagnosis of myxoma. Loss of heterozygosity was not present, suggesting that haploinsufficiency alone was responsible for tumorigenesis of this eyelid lesion. Published 2004 Wiley‐Liss, Inc.

Collaboration


Dive into the Benjamin I. Rubin's collaboration.

Top Co-Authors

Avatar

Ekaterini Tsilou

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert B. Nussenblatt

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

William A. Gahl

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Chi-Chao Chan

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Rafael C. Caruso

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Scott M. Whitcup

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

George F. Reed

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alan G. Palestine

University of Colorado Denver

View shared research outputs
Researchain Logo
Decentralizing Knowledge